Recruiting
Phase 3

LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

Sponsor:

Tenax Therapeutics, Inc.

Code:

NCT05983250

Conditions

Pulmonary Hypertension

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

TNX-103

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information